The human gut microbiome plays an important role in many aspects of human health and disease, including colorectal cancer, inflammatory bowel disease and type 2 diabetes. However, there are over 3,000 gut bacterial species across the world that still remain uncultured to date, and therefore inaccessible to experimental manipulation.
In this talk I will showcase how large-scale metagenomic approaches have allowed us to shed new light into the role of the uncultured microbiome across various diseases and its potential diagnostic application.
I will also highlight how studying the interaction between the microbiome and opportunistic pathogens in the gut may help develop alternative therapeutic strategies for mitigating the emergence of multidrug-resistant infections worldwide.